MAJOR DEPRESSIVE DISORDER:
Introduction
Psychiatry Education Forum Academy continues to provide high-quality, evidence-based & practice-oriented discussions to improve your clinical decision-making.
It is known that close to 50% of patients with major depressive episodes may not achieve remission after the trials of first-line antidepressants, and only around one-third will achieve remission. This is clinically relevant for both patients and medical professionals, as chances of remission reduce with each subsequent trial. This lecture series has discussed the ten available augmentation options for major depressive disorder in the following 10 sections:
LECTURE SCHEDULE
(1) ATYPICAL ANTIPSYCHOTICS
- Comparing International Guidelines: line of recommendations for atypical antipsychotics for MDD augmentation.
- International Guidelines versus FDA Indications: How do guideline recommendations differ from FDA-approved indications?
- First-Line Recommendation: Which atypical antipsychotics are considered the first choice as an augmentation strategy?
- Second & Third Line Recommendation: Which atypical antipsychotics are considered second-line and third-line for MDD augmentation?
- Can low-dose antipsychotics help with depression augmentation?
- Recommended Dose for each atypical antipsychotic: based on various international guidelines recommendations.
- Which Quetiapine formulation is preferred: XR or IR?
- Comparing atypical antipsychotics with Lithium: is one better than the other for MDD augmentation?
One Presentation Slide from this Discussion:
(2) LITHIUM
- Comparing International Guidelines: line of recommendations for Lithium for MDD augmentation.
- Can low-dose lithium help with depression augmentation?
- Recommended Dose for Lithium: based on various international guidelines recommendations.
- Better Outcome Predictors: Which clinical factors are associated with better outcome rates with Lithium?
- Timeline of Response: When can we expect a response with lithium treatment?
- How long to continue Lithium for: comparing international guidelines recommendations.
- Comparing Lithium with: (a) atypical antipsychotics & (b) T3 (triiodothyronine): is one better than the other for MDD augmentation?
One Presentation Slide from this Discussion:
(3) THYROID HORMONE
- Comparing International Guidelines: line of recommendations for Thyroid hormone for MDD augmentation.
- T3 or T4: which one is recommended?
- Recommended Dose for Thyroid hormone: based on various international guidelines recommendations.
- Timeline of Response: When can we expect a response with thyroid hormone treatment?
- Supraphysiological T4 Dose: (a) Is this safe; (b) Who is a good candidate?
- Dose Conversion: between various thyroid hormone formulations.
- Laboratory Monitoring Guidelines: which laboratory & radiological investigations are recommended during thyroid hormone treatment?
- Cautions & Contraindications: with thyroid hormone treatment.
- Comparing Thyroid hormone with (a) atypical antipsychotics & (b) lithium: is one better than the other for MDD augmentation?
One Presentation Slide from this Discussion:
(4) L-METHYLFOLATE
- Mechanism of Action: role of L-Methylfolate for MDD augmentation.
- High-Risk Population: who will benefit from L-Methylfolate augmentation?
- Drug Interactions: that can reduce L-Methylfolate.
- Lab Workup: needed before considering L-Methylfolate treatment.
- Recommended Dose of L-Methylfolate: for MDD augmentation.
- Duration of Treatment: How long to continue L-Methyloflate for MDD augmentation?
One Presentation Slide from this Discussion:
(5) LAMOTRIGINE
- Comparing International Guidelines: line of recommendations for Lamotrigine for MDD augmentation.
- Which patient population subtype: has shown a better response to lamotrigine for MDD augmentation?
- Recommended Dose for Lamotrigine: based on various international guidelines recommendations.
- How long to conitnue lamotrgine for MDD augmentation?
- Comparing Lamotrigine versus Lithium: is one better than the other for MDD augmentation?
One Presentation Slide from this Discussion:
(6) STIMULANTS
- Comparing International Guidelines: line of recommendations for Stimulants for MDD augmentation.
- Which patient population subtype: has shown a better response to stimulants for MDD augmentation?
- Recommended Dose for Stimulants: based on various international guidelines recommendations.
One Presentation Slide from this Discussion:
(7) BUSPIRONE
- Comparing International Guidelines: line of recommendations for Buspirone for MDD augmentation.
- Which patient population subtype: has shown a better response to buspirone for MDD augmentation?
- Recommended Dose for Buspirone: based on various international guidelines recommendations.
- Buspirone versus Bupropion: is one better than the other for MDD augmentation?
- STAR*D Trial: Comparing the efficacy of buspirone versus cognitive therapy as a second line treatment for MDD augmentation.
One Presentation Slide from this Discussion:
(8) PRAMIPEXOLE
- Mechanism of Action: behind Pramipexole’s efficacy for MDD augmentation.
- Who is a Good Candidate: for Pramipexole trial?
- Recommended Dose for Pramipexole: how to initiate & titrate in adults and elderly patients?
- Onset of Response: how long will it take to achieve a response after reaching the therapeutic dose?
- Side Effects: with pramipexole treatment.
One Presentation Slide from this Discussion:
(9) S-Adenosyl Methionine (SAMe)
- Mechanism of Action: behind SAMe efficacy for MDD augmentation.
- SAMe Preferred over Antidepressants? Which patient population will benefit more from SAMe compared to antidepressants?
- Recommended Dose of SAMe: for MDD augmentation.
- Guideline Recommendation: which guideline recommends SAMe for MDD augmentation?
One Presentation Slide from this Discussion:
(10) LOW DOSE NALTREXONE (LDN)
- LDN Definition: How is LDN different from Naltrexone?
- Mechanism of action: of LDN for MDD augmentation.
- Recommended Dose for LDN: for MDD augmentation.
- Side Effects & Cautions: with LDN use for MDD.
- Article Discussion: of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
One Presentation Slide from this Discussion:
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN PSYCHIATRY EDUCATION FORUM ACADEMY MEMBERSHIP
This is a closed membership for medical professionals only.
- 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice.
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Coffee Club: contain short discussions with clinical experts in the field of psychiatry.
- Clinical Case Discussions: Discussions of clinical cases from our daily clinical practice.
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections.
- Goal: is to have all important clinically relevant topics in one place for ease of access.
JOIN ACADEMY MEMBERSHIP:
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com
